Global Targeted Lung Cancer Drugs Market Growth (Status and Outlook) 2026-2032
The global Targeted Lung Cancer Drugs market size is predicted to grow from US$ 18786 million in 2025 to US$ 35013 million in 2032; it is expected to grow at a CAGR of 9.3% from 2026 to 2032.
Targeted Lung Cancer Drugs are prescription anticancer medicines designed to inhibit molecular abnormalities, signaling pathways or cell-surface targets that promote the development and progression of lung cancer. The research scope covers EGFR-, ALK-, ROS1-, KRAS G12C-, MET-, RET-, BRAF/MEK-, HER2-, NTRK- and VEGF/VEGFR-directed therapies. Major product forms include small-molecule tyrosine kinase inhibitors, RAS inhibitors, monoclonal antibodies, bispecific antibodies and antibody-drug conjugates, delivered primarily as oral tablets or capsules and intravenous or subcutaneous formulations. Treatment selection is generally guided by tumor histology, disease stage, genomic alterations and companion diagnostic results obtained through tissue testing, next-generation sequencing or liquid biopsy. The market primarily serves biomarker-defined non-small cell lung cancer, including lung adenocarcinoma and selected squamous-cell carcinoma populations, while also covering applicable targeted treatment settings in small cell lung cancer. Clinical applications extend from advanced and metastatic disease to postoperative adjuvant treatment, unresectable locally advanced disease, brain metastases and treatment following acquired drug resistance.
Key Findings
The average gross profit margin of this product is 82%
Non-small cell lung cancer remains the core commercial application
EGFR-targeted therapies form the most mature product segment
Small-molecule kinase inhibitors remain the dominant therapeutic class
Combination and post-resistance regimens are expanding treatment value
North America leads commercialization while East Asia drives strategic demand
Market Trends
Targeted Lung Cancer Drugs are moving from a model centered on single-gene testing and later-line monotherapy toward comprehensive biomarker profiling and treatment across multiple disease stages. Multiplex next-generation sequencing is increasingly preferred because it can evaluate mutations, fusions and other actionable alterations within limited tissue samples, while circulating tumor DNA testing supports treatment selection when tissue is unavailable and helps identify resistance mechanisms after disease progression. Product development is also shifting toward earlier intervention, with targeted agents extending from metastatic disease into postoperative adjuvant treatment and unresectable stage III settings. Within advanced disease, first-line combinations, antibody-based regimens and therapies designed for patients progressing after established tyrosine kinase inhibitors are becoming more important. Development priorities increasingly emphasize intracranial activity, broader mutation coverage, longer response duration and improved tolerability. Oral therapies retain strong clinical convenience, while subcutaneous formulations of antibody products are emerging as an approach to reduce administration time and improve treatment efficiency. These changes are transforming the market from isolated mutation-specific niches into an integrated precision-oncology system linking diagnostics, drug selection, resistance monitoring and sequential treatment.
Market Dynamics
Drivers
The principal driver is the substantial clinical burden of lung cancer and the continuing need for treatments that improve disease control in biomarker-defined patient populations. Broader adoption of molecular testing is increasing the identification of actionable alterations, allowing more patients to enter targeted treatment pathways. Expansion of testing from EGFR, ALK and ROS1 toward KRAS, MET, RET, BRAF, HER2 and NTRK has enlarged the addressable treatment population and supported the development of increasingly specialized products. Regulatory approvals across first-line, post-resistance, locally advanced and adjuvant settings are extending treatment duration and increasing the number of eligible clinical scenarios. Improved central nervous system penetration, more effective resistance-directed drugs and closer integration between companion diagnostics and therapeutic development further support market demand.
Restraints
Market development is constrained by the high combined cost of genomic testing, targeted medicines and long-term treatment monitoring. Access to comprehensive molecular diagnostics remains uneven across healthcare systems, and insufficient tissue, long testing turnaround times or incomplete biomarker panels can prevent eligible patients from receiving matched therapy. Many targetable alterations occur in relatively small patient populations, limiting commercial scale and increasing the development cost per eligible patient. Targeted agents may also produce mutation-specific adverse events, drug interactions and cumulative toxicities that require specialist management. Reimbursement assessments, price negotiations and differences in national treatment guidelines can delay adoption after regulatory approval, particularly in healthcare systems with restricted oncology budgets. These factors create a persistent gap between scientific availability and real-world treatment penetration.
Opportunities
The strongest opportunities lie in expanding targeted treatment into earlier disease stages, addressing acquired resistance and serving molecular subgroups that currently have limited treatment options. Postoperative adjuvant therapy and treatment following chemoradiation can substantially enlarge the treated population beyond metastatic disease. Combination strategies involving small molecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and chemotherapy provide opportunities to suppress multiple signaling pathways and delay resistance. Improved liquid-biopsy sensitivity may enable faster treatment selection, longitudinal monitoring and earlier detection of molecular progression. Additional opportunities exist in developing agents with stronger brain penetration, broader activity across uncommon mutations and more convenient dosing formulations. In emerging healthcare markets, expansion of NGS capacity, inclusion of targeted medicines in reimbursement systems and locally developed products can convert a large diagnosed lung cancer population into more accessible precision-treatment demand.
Challenges
Acquired resistance remains the central scientific and commercial challenge because tumors can develop secondary mutations, activate bypass pathways or undergo histological transformation during treatment. The growing number of available therapies also makes treatment sequencing increasingly complex, particularly when several options are available for the same molecular alteration or after progression on a first-line agent. Rare mutations create difficulties in patient recruitment, clinical-trial design and generation of comparative evidence. Companies must coordinate therapeutic development with validated diagnostic assays while managing differences in regulatory requirements, biomarker definitions and reimbursement standards across markets. Intensifying competition within mature targets may shorten product differentiation cycles and increase pressure on pricing, clinical evidence and lifecycle management. Long-term success therefore depends not only on achieving initial response but also on demonstrating durable disease control, intracranial efficacy, manageable safety and a clear position within increasingly complex treatment pathways.
Industry Chain Analysis
The upstream segment of the Targeted Lung Cancer Drugs industry includes active pharmaceutical ingredients, advanced intermediates, chemical reagents, biologic cell lines, culture media, excipients and specialized manufacturing materials. Antibody-drug conjugates additionally require antibodies, cytotoxic payloads, linkers and controlled conjugation technologies. Companion-diagnostic inputs, including sequencing reagents, probes, reference materials and sample-preparation systems, form another strategically important upstream component because biomarker confirmation determines patient eligibility. The reliability of raw materials, process consistency and intellectual-property control directly influence manufacturing cost, regulatory compliance and supply continuity.
The midstream segment covers target discovery, molecular design, preclinical validation, clinical development, drug-substance and finished-dose manufacturing, quality control, regulatory registration and post-marketing evidence generation. Small-molecule products generally benefit from scalable chemical synthesis and oral delivery but require substantial investment in molecular selectivity and resistance management. Antibodies, bispecific products and antibody-drug conjugates involve more complex manufacturing, analytical control and cold-chain requirements, creating higher technical barriers. Downstream participants include molecular pathology laboratories, hospitals, oncology centers, specialty pharmacies, distributors and reimbursement institutions. Value is created through the integration of proprietary molecules, companion diagnostics, clinical evidence, regulatory access and physician adoption. Products with differentiated efficacy in first-line treatment, resistance settings or brain metastases generally capture greater value, while mature targets face increasing pressure from therapeutic alternatives, reimbursement negotiations and lifecycle competition.
Segment Insights
By molecular target, EGFR-targeted drugs represent the most mature segment because of established testing practices, multiple generations of tyrosine kinase inhibitors and broad use across advanced, adjuvant and locally advanced disease. ALK-, ROS1-, RET- and MET-directed therapies address smaller but clinically well-defined populations, where high biomarker specificity supports substantial therapeutic value. KRAS G12C inhibitors have expanded targeted treatment into a historically difficult signaling pathway, while HER2-targeted drugs, antibody-drug conjugates and bispecific antibodies represent important areas of product innovation. BRAF/MEK-, NTRK- and VEGF/VEGFR-directed products provide additional treatment options, although their clinical positioning varies by mutation frequency, disease stage and availability of competing regimens.
By therapeutic class, small-molecule tyrosine kinase inhibitors remain dominant because they cover most established oncogenic drivers, support oral administration and can be optimized for central nervous system penetration. Monoclonal antibodies and bispecific antibodies are becoming more relevant where simultaneous pathway blockade or immune-mediated tumor-cell elimination can address complex resistance biology. Antibody-drug conjugates provide a differentiated route for delivering cytotoxic payloads to target-expressing tumors. Biomarker-matched monotherapy remains the foundation of the market, but targeted combinations and post-resistance therapies are gaining strategic importance. Oral tablets and capsules account for the principal dosage-form structure, while intravenous products dominate antibody-based therapy and subcutaneous formulations offer an emerging convenience advantage.
Downstream Market Opportunities
Advanced and metastatic non-small cell lung cancer remains the largest downstream application because molecular testing is most established in this setting and treatment is frequently continued until progression or unacceptable toxicity. Lung adenocarcinoma accounts for the principal biomarker-matched population, while selected squamous-cell carcinoma patients may also benefit when actionable alterations are detected. Early-stage resectable disease, postoperative adjuvant therapy and unresectable locally advanced disease are becoming increasingly important as targeted medicines move closer to initial diagnosis. Patients with brain metastases create demand for agents with reliable intracranial activity, while acquired resistance generates recurring opportunities for repeat testing, next-generation inhibitors and combination regimens. Small cell lung cancer remains a more selective targeted-treatment application, but increasing understanding of molecular subtypes and cell-surface targets may support additional specialized therapies over the longer term.
Regional Insights
This report assesses North America as the leading commercial region for Targeted Lung Cancer Drugs, supported by broad molecular-testing infrastructure, relatively early regulatory access to new therapies, specialist oncology networks and comparatively strong capacity to fund high-value precision medicines. The United States remains an important launch market for mutation-specific therapies and new treatment combinations, enabling companies to establish clinical adoption before broader international expansion. Europe is also a mature market, although health-technology assessment, national reimbursement negotiations and differences in diagnostic access can produce variation in adoption among countries.
East Asia represents one of the most strategically important demand and innovation regions. The comparatively high prevalence of actionable molecular alterations in Asian lung adenocarcinoma populations, particularly EGFR mutations, supports extensive testing, clinical development and targeted-drug utilization. China combines a large lung cancer patient population with expanding genomic-testing capacity, domestic drug development and broader reimbursement coverage, while Japan maintains sophisticated diagnostic and oncology-treatment systems. Other Asian and emerging markets offer meaningful long-term potential, but market conversion depends on laboratory infrastructure, affordability, regulatory timelines and reimbursement access. Regional competition will therefore be shaped by both disease epidemiology and the ability of healthcare systems to connect patients with testing and matched treatment.
Competitive Landscape Analysis
The competitive landscape combines multinational pharmaceutical groups with broad global oncology platforms and China-based companies focused on locally prevalent mutations, differentiated molecules and domestic market access. AstraZeneca, F. Hoffmann-La Roche, Pfizer, Novartis, Johnson & Johnson, Amgen, Bristol Myers Squibb, Eli Lilly, Takeda Pharmaceutical, Boehringer Ingelheim, Merck KGaA, Bayer and Daiichi Sankyo compete through established targeted-drug portfolios, multinational clinical-development capabilities, companion-diagnostic partnerships and lifecycle expansion into earlier treatment lines or combination regimens. Their competitive advantages generally derive from global regulatory execution, large clinical-trial networks, physician familiarity and the ability to support sequential treatment strategies. Shanghai Allist Pharmaceuticals, Betta Pharmaceuticals, Jiangsu Hansoh Pharmaceutical Group, Dizal Pharmaceutical, HUTCHMED China, Shanghai Haihe Biopharma, Innovent Biologics and Chia Tai Tianqing Pharmaceutical Group strengthen competition through China-centered clinical development, local commercialization capabilities, pricing flexibility and products designed around clinically relevant molecular subgroups. Competition is increasingly shifting from the availability of a drug for a specific target toward comparative efficacy, resistance coverage, brain-metastasis control, safety, dosing convenience and positioning within treatment sequences. Companies with integrated diagnostic strategies, differentiated clinical evidence and access to both international and regional markets are better positioned to sustain product value as individual target categories become more crowded.
Report Scope
LPI (LP Information)' newest research report, the “Targeted Lung Cancer Drugs Industry Forecast” looks at past sales and reviews total world Targeted Lung Cancer Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Lung Cancer Drugs sales for 2026 through 2032. With Targeted Lung Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Lung Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Targeted Lung Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Lung Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Lung Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Lung Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Lung Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Lung Cancer Drugs market by product type, application, key players and key regions and countries.
Market Segmentation
Targeted Lung Cancer Drugs are prescription anticancer medicines designed to inhibit molecular abnormalities, signaling pathways or cell-surface targets that promote the development and progression of lung cancer. The research scope covers EGFR-, ALK-, ROS1-, KRAS G12C-, MET-, RET-, BRAF/MEK-, HER2-, NTRK- and VEGF/VEGFR-directed therapies. Major product forms include small-molecule tyrosine kinase inhibitors, RAS inhibitors, monoclonal antibodies, bispecific antibodies and antibody-drug conjugates, delivered primarily as oral tablets or capsules and intravenous or subcutaneous formulations. Treatment selection is generally guided by tumor histology, disease stage, genomic alterations and companion diagnostic results obtained through tissue testing, next-generation sequencing or liquid biopsy. The market primarily serves biomarker-defined non-small cell lung cancer, including lung adenocarcinoma and selected squamous-cell carcinoma populations, while also covering applicable targeted treatment settings in small cell lung cancer. Clinical applications extend from advanced and metastatic disease to postoperative adjuvant treatment, unresectable locally advanced disease, brain metastases and treatment following acquired drug resistance.
Key Findings
The average gross profit margin of this product is 82%
Non-small cell lung cancer remains the core commercial application
EGFR-targeted therapies form the most mature product segment
Small-molecule kinase inhibitors remain the dominant therapeutic class
Combination and post-resistance regimens are expanding treatment value
North America leads commercialization while East Asia drives strategic demand
Market Trends
Targeted Lung Cancer Drugs are moving from a model centered on single-gene testing and later-line monotherapy toward comprehensive biomarker profiling and treatment across multiple disease stages. Multiplex next-generation sequencing is increasingly preferred because it can evaluate mutations, fusions and other actionable alterations within limited tissue samples, while circulating tumor DNA testing supports treatment selection when tissue is unavailable and helps identify resistance mechanisms after disease progression. Product development is also shifting toward earlier intervention, with targeted agents extending from metastatic disease into postoperative adjuvant treatment and unresectable stage III settings. Within advanced disease, first-line combinations, antibody-based regimens and therapies designed for patients progressing after established tyrosine kinase inhibitors are becoming more important. Development priorities increasingly emphasize intracranial activity, broader mutation coverage, longer response duration and improved tolerability. Oral therapies retain strong clinical convenience, while subcutaneous formulations of antibody products are emerging as an approach to reduce administration time and improve treatment efficiency. These changes are transforming the market from isolated mutation-specific niches into an integrated precision-oncology system linking diagnostics, drug selection, resistance monitoring and sequential treatment.
Market Dynamics
Drivers
The principal driver is the substantial clinical burden of lung cancer and the continuing need for treatments that improve disease control in biomarker-defined patient populations. Broader adoption of molecular testing is increasing the identification of actionable alterations, allowing more patients to enter targeted treatment pathways. Expansion of testing from EGFR, ALK and ROS1 toward KRAS, MET, RET, BRAF, HER2 and NTRK has enlarged the addressable treatment population and supported the development of increasingly specialized products. Regulatory approvals across first-line, post-resistance, locally advanced and adjuvant settings are extending treatment duration and increasing the number of eligible clinical scenarios. Improved central nervous system penetration, more effective resistance-directed drugs and closer integration between companion diagnostics and therapeutic development further support market demand.
Restraints
Market development is constrained by the high combined cost of genomic testing, targeted medicines and long-term treatment monitoring. Access to comprehensive molecular diagnostics remains uneven across healthcare systems, and insufficient tissue, long testing turnaround times or incomplete biomarker panels can prevent eligible patients from receiving matched therapy. Many targetable alterations occur in relatively small patient populations, limiting commercial scale and increasing the development cost per eligible patient. Targeted agents may also produce mutation-specific adverse events, drug interactions and cumulative toxicities that require specialist management. Reimbursement assessments, price negotiations and differences in national treatment guidelines can delay adoption after regulatory approval, particularly in healthcare systems with restricted oncology budgets. These factors create a persistent gap between scientific availability and real-world treatment penetration.
Opportunities
The strongest opportunities lie in expanding targeted treatment into earlier disease stages, addressing acquired resistance and serving molecular subgroups that currently have limited treatment options. Postoperative adjuvant therapy and treatment following chemoradiation can substantially enlarge the treated population beyond metastatic disease. Combination strategies involving small molecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and chemotherapy provide opportunities to suppress multiple signaling pathways and delay resistance. Improved liquid-biopsy sensitivity may enable faster treatment selection, longitudinal monitoring and earlier detection of molecular progression. Additional opportunities exist in developing agents with stronger brain penetration, broader activity across uncommon mutations and more convenient dosing formulations. In emerging healthcare markets, expansion of NGS capacity, inclusion of targeted medicines in reimbursement systems and locally developed products can convert a large diagnosed lung cancer population into more accessible precision-treatment demand.
Challenges
Acquired resistance remains the central scientific and commercial challenge because tumors can develop secondary mutations, activate bypass pathways or undergo histological transformation during treatment. The growing number of available therapies also makes treatment sequencing increasingly complex, particularly when several options are available for the same molecular alteration or after progression on a first-line agent. Rare mutations create difficulties in patient recruitment, clinical-trial design and generation of comparative evidence. Companies must coordinate therapeutic development with validated diagnostic assays while managing differences in regulatory requirements, biomarker definitions and reimbursement standards across markets. Intensifying competition within mature targets may shorten product differentiation cycles and increase pressure on pricing, clinical evidence and lifecycle management. Long-term success therefore depends not only on achieving initial response but also on demonstrating durable disease control, intracranial efficacy, manageable safety and a clear position within increasingly complex treatment pathways.
Industry Chain Analysis
The upstream segment of the Targeted Lung Cancer Drugs industry includes active pharmaceutical ingredients, advanced intermediates, chemical reagents, biologic cell lines, culture media, excipients and specialized manufacturing materials. Antibody-drug conjugates additionally require antibodies, cytotoxic payloads, linkers and controlled conjugation technologies. Companion-diagnostic inputs, including sequencing reagents, probes, reference materials and sample-preparation systems, form another strategically important upstream component because biomarker confirmation determines patient eligibility. The reliability of raw materials, process consistency and intellectual-property control directly influence manufacturing cost, regulatory compliance and supply continuity.
The midstream segment covers target discovery, molecular design, preclinical validation, clinical development, drug-substance and finished-dose manufacturing, quality control, regulatory registration and post-marketing evidence generation. Small-molecule products generally benefit from scalable chemical synthesis and oral delivery but require substantial investment in molecular selectivity and resistance management. Antibodies, bispecific products and antibody-drug conjugates involve more complex manufacturing, analytical control and cold-chain requirements, creating higher technical barriers. Downstream participants include molecular pathology laboratories, hospitals, oncology centers, specialty pharmacies, distributors and reimbursement institutions. Value is created through the integration of proprietary molecules, companion diagnostics, clinical evidence, regulatory access and physician adoption. Products with differentiated efficacy in first-line treatment, resistance settings or brain metastases generally capture greater value, while mature targets face increasing pressure from therapeutic alternatives, reimbursement negotiations and lifecycle competition.
Segment Insights
By molecular target, EGFR-targeted drugs represent the most mature segment because of established testing practices, multiple generations of tyrosine kinase inhibitors and broad use across advanced, adjuvant and locally advanced disease. ALK-, ROS1-, RET- and MET-directed therapies address smaller but clinically well-defined populations, where high biomarker specificity supports substantial therapeutic value. KRAS G12C inhibitors have expanded targeted treatment into a historically difficult signaling pathway, while HER2-targeted drugs, antibody-drug conjugates and bispecific antibodies represent important areas of product innovation. BRAF/MEK-, NTRK- and VEGF/VEGFR-directed products provide additional treatment options, although their clinical positioning varies by mutation frequency, disease stage and availability of competing regimens.
By therapeutic class, small-molecule tyrosine kinase inhibitors remain dominant because they cover most established oncogenic drivers, support oral administration and can be optimized for central nervous system penetration. Monoclonal antibodies and bispecific antibodies are becoming more relevant where simultaneous pathway blockade or immune-mediated tumor-cell elimination can address complex resistance biology. Antibody-drug conjugates provide a differentiated route for delivering cytotoxic payloads to target-expressing tumors. Biomarker-matched monotherapy remains the foundation of the market, but targeted combinations and post-resistance therapies are gaining strategic importance. Oral tablets and capsules account for the principal dosage-form structure, while intravenous products dominate antibody-based therapy and subcutaneous formulations offer an emerging convenience advantage.
Downstream Market Opportunities
Advanced and metastatic non-small cell lung cancer remains the largest downstream application because molecular testing is most established in this setting and treatment is frequently continued until progression or unacceptable toxicity. Lung adenocarcinoma accounts for the principal biomarker-matched population, while selected squamous-cell carcinoma patients may also benefit when actionable alterations are detected. Early-stage resectable disease, postoperative adjuvant therapy and unresectable locally advanced disease are becoming increasingly important as targeted medicines move closer to initial diagnosis. Patients with brain metastases create demand for agents with reliable intracranial activity, while acquired resistance generates recurring opportunities for repeat testing, next-generation inhibitors and combination regimens. Small cell lung cancer remains a more selective targeted-treatment application, but increasing understanding of molecular subtypes and cell-surface targets may support additional specialized therapies over the longer term.
Regional Insights
This report assesses North America as the leading commercial region for Targeted Lung Cancer Drugs, supported by broad molecular-testing infrastructure, relatively early regulatory access to new therapies, specialist oncology networks and comparatively strong capacity to fund high-value precision medicines. The United States remains an important launch market for mutation-specific therapies and new treatment combinations, enabling companies to establish clinical adoption before broader international expansion. Europe is also a mature market, although health-technology assessment, national reimbursement negotiations and differences in diagnostic access can produce variation in adoption among countries.
East Asia represents one of the most strategically important demand and innovation regions. The comparatively high prevalence of actionable molecular alterations in Asian lung adenocarcinoma populations, particularly EGFR mutations, supports extensive testing, clinical development and targeted-drug utilization. China combines a large lung cancer patient population with expanding genomic-testing capacity, domestic drug development and broader reimbursement coverage, while Japan maintains sophisticated diagnostic and oncology-treatment systems. Other Asian and emerging markets offer meaningful long-term potential, but market conversion depends on laboratory infrastructure, affordability, regulatory timelines and reimbursement access. Regional competition will therefore be shaped by both disease epidemiology and the ability of healthcare systems to connect patients with testing and matched treatment.
Competitive Landscape Analysis
The competitive landscape combines multinational pharmaceutical groups with broad global oncology platforms and China-based companies focused on locally prevalent mutations, differentiated molecules and domestic market access. AstraZeneca, F. Hoffmann-La Roche, Pfizer, Novartis, Johnson & Johnson, Amgen, Bristol Myers Squibb, Eli Lilly, Takeda Pharmaceutical, Boehringer Ingelheim, Merck KGaA, Bayer and Daiichi Sankyo compete through established targeted-drug portfolios, multinational clinical-development capabilities, companion-diagnostic partnerships and lifecycle expansion into earlier treatment lines or combination regimens. Their competitive advantages generally derive from global regulatory execution, large clinical-trial networks, physician familiarity and the ability to support sequential treatment strategies. Shanghai Allist Pharmaceuticals, Betta Pharmaceuticals, Jiangsu Hansoh Pharmaceutical Group, Dizal Pharmaceutical, HUTCHMED China, Shanghai Haihe Biopharma, Innovent Biologics and Chia Tai Tianqing Pharmaceutical Group strengthen competition through China-centered clinical development, local commercialization capabilities, pricing flexibility and products designed around clinically relevant molecular subgroups. Competition is increasingly shifting from the availability of a drug for a specific target toward comparative efficacy, resistance coverage, brain-metastasis control, safety, dosing convenience and positioning within treatment sequences. Companies with integrated diagnostic strategies, differentiated clinical evidence and access to both international and regional markets are better positioned to sustain product value as individual target categories become more crowded.
Report Scope
LPI (LP Information)' newest research report, the “Targeted Lung Cancer Drugs Industry Forecast” looks at past sales and reviews total world Targeted Lung Cancer Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Lung Cancer Drugs sales for 2026 through 2032. With Targeted Lung Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Lung Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Targeted Lung Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Lung Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Lung Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Lung Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Lung Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Lung Cancer Drugs market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- EGFR-Targeted Drugs
- ALK-Targeted Drugs
- ROS1-Targeted Drugs
- KRAS G12C-Targeted Drugs
- MET-Targeted Drugs
- RET-Targeted Drugs
Segmentation by Drugs Type:
- Small-Molecule Tyrosine Kinase Inhibitors
- Small-Molecule RAS Inhibitors
- Monoclonal Antibodies
- Bispecific Antibodies
- Antibody-Drug Conjugates
Segmentation by Route of Administration:
- Oral Tablets
- Oral Capsules
- Oral Solutions
- Intravenous Injections
- Subcutaneous Injections
Segmentation by Application:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Lung Adenocarcinoma
- Lung Squamous Cell Carcinoma
- Early-Stage Resectable Lung Cancer
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Roche
- Pfizer
- Novartis
- Johnson & Johnson
- Amgen
- Bristol Myers Squibb
- Eli Lilly and Company
- Takeda
- Boehringer Ingelheim
- Merck
- Bayer
- Daiichi Sankyo Company
- Shanghai Allist Pharmaceuticals
- Betta Pharmaceuticals
- Jiangsu Hansoh Pharmaceutical
- Dizal (Jiangsu) Pharmaceutical
- HUTCHMED (China) Limited
- Innovent Biologics
- Chia Tai Tianqing Pharmaceutical
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Lung Cancer Drugs Market Size (2021-2032)
2.1.2 Targeted Lung Cancer Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Lung Cancer Drugs by Country/Region (2021, 2025 & 2032)
2.2 Targeted Lung Cancer Drugs Segment by Type
2.2.1 EGFR-Targeted Drugs
2.2.2 ALK-Targeted Drugs
2.2.3 ROS1-Targeted Drugs
2.2.4 KRAS G12C-Targeted Drugs
2.2.5 MET-Targeted Drugs
2.2.6 RET-Targeted Drugs
2.2.7 Targeted Lung Cancer Drugs Market Size by Type
2.2.7.1 Targeted Lung Cancer Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
2.3 Targeted Lung Cancer Drugs Segment by Drugs Type
2.3.1 Small-Molecule Tyrosine Kinase Inhibitors
2.3.2 Small-Molecule RAS Inhibitors
2.3.3 Monoclonal Antibodies
2.3.4 Bispecific Antibodies
2.3.5 Antibody-Drug Conjugates
2.3.6 Targeted Lung Cancer Drugs Market Size by Drugs Type
2.3.6.1 Targeted Lung Cancer Drugs Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type (2021-2026)
2.4 Targeted Lung Cancer Drugs Segment by Route of Administration
2.4.1 Oral Tablets
2.4.2 Oral Capsules
2.4.3 Oral Solutions
2.4.4 Intravenous Injections
2.4.5 Subcutaneous Injections
2.4.6 Targeted Lung Cancer Drugs Market Size by Route of Administration
2.4.6.1 Targeted Lung Cancer Drugs Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.6.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration (2021-2026)
2.5 Targeted Lung Cancer Drugs Segment by Application
2.5.1 Non-Small Cell Lung Cancer
2.5.2 Small Cell Lung Cancer
2.5.3 Lung Adenocarcinoma
2.5.4 Lung Squamous Cell Carcinoma
2.5.5 Early-Stage Resectable Lung Cancer
2.5.6 Other
2.5.7 Targeted Lung Cancer Drugs Market Size by Application
2.5.7.1 Targeted Lung Cancer Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
3 TARGETED LUNG CANCER DRUGS MARKET SIZE BY PLAYER
3.1 Targeted Lung Cancer Drugs Market Size Market Share by Player
3.1.1 Global Targeted Lung Cancer Drugs Revenue by Player (2021-2026)
3.1.2 Global Targeted Lung Cancer Drugs Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Lung Cancer Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED LUNG CANCER DRUGS BY REGION
4.1 Targeted Lung Cancer Drugs Market Size by Region (2021-2026)
4.2 Global Targeted Lung Cancer Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.4 APAC Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.5 Europe Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Lung Cancer Drugs Market Size by Country (2021-2026)
5.2 Americas Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
5.3 Americas Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Lung Cancer Drugs Market Size by Region (2021-2026)
6.2 APAC Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
6.3 APAC Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Lung Cancer Drugs Market Size by Country (2021-2026)
7.2 Europe Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
7.3 Europe Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Lung Cancer Drugs by Region (2021-2026)
8.2 Middle East & Africa Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED LUNG CANCER DRUGS MARKET FORECAST
10.1 Global Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.1.1 Global Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.1.2 Americas Targeted Lung Cancer Drugs Forecast
10.1.3 APAC Targeted Lung Cancer Drugs Forecast
10.1.4 Europe Targeted Lung Cancer Drugs Forecast
10.1.5 Middle East & Africa Targeted Lung Cancer Drugs Forecast
10.2 Americas Targeted Lung Cancer Drugs Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Lung Cancer Drugs Forecast
10.2.2 Canada Market Targeted Lung Cancer Drugs Forecast
10.2.3 Mexico Market Targeted Lung Cancer Drugs Forecast
10.2.4 Brazil Market Targeted Lung Cancer Drugs Forecast
10.3 APAC Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.3.1 China Targeted Lung Cancer Drugs Market Forecast
10.3.2 Japan Market Targeted Lung Cancer Drugs Forecast
10.3.3 Korea Market Targeted Lung Cancer Drugs Forecast
10.3.4 Southeast Asia Market Targeted Lung Cancer Drugs Forecast
10.3.5 India Market Targeted Lung Cancer Drugs Forecast
10.3.6 Australia Market Targeted Lung Cancer Drugs Forecast
10.4 Europe Targeted Lung Cancer Drugs Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Lung Cancer Drugs Forecast
10.4.2 France Market Targeted Lung Cancer Drugs Forecast
10.4.3 UK Market Targeted Lung Cancer Drugs Forecast
10.4.4 Italy Market Targeted Lung Cancer Drugs Forecast
10.4.5 Russia Market Targeted Lung Cancer Drugs Forecast
10.5 Middle East & Africa Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Lung Cancer Drugs Forecast
10.5.2 South Africa Market Targeted Lung Cancer Drugs Forecast
10.5.3 Israel Market Targeted Lung Cancer Drugs Forecast
10.5.4 Turkey Market Targeted Lung Cancer Drugs Forecast
10.6 Global Targeted Lung Cancer Drugs Forecast by Type (2027-2032)
10.7 Global Targeted Lung Cancer Drugs Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Lung Cancer Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Targeted Lung Cancer Drugs Product Offered
11.1.3 AstraZeneca Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Targeted Lung Cancer Drugs Product Offered
11.2.3 Roche Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Targeted Lung Cancer Drugs Product Offered
11.3.3 Pfizer Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Targeted Lung Cancer Drugs Product Offered
11.4.3 Novartis Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Targeted Lung Cancer Drugs Product Offered
11.5.3 Johnson & Johnson Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Amgen
11.6.1 Amgen Company Information
11.6.2 Amgen Targeted Lung Cancer Drugs Product Offered
11.6.3 Amgen Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Amgen Main Business Overview
11.6.5 Amgen Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Targeted Lung Cancer Drugs Product Offered
11.7.3 Bristol Myers Squibb Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Information
11.8.2 Eli Lilly and Company Targeted Lung Cancer Drugs Product Offered
11.8.3 Eli Lilly and Company Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Eli Lilly and Company Main Business Overview
11.8.5 Eli Lilly and Company Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Targeted Lung Cancer Drugs Product Offered
11.9.3 Takeda Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Targeted Lung Cancer Drugs Product Offered
11.10.3 Boehringer Ingelheim Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Boehringer Ingelheim Main Business Overview
11.10.5 Boehringer Ingelheim Latest Developments
11.11 Merck
11.11.1 Merck Company Information
11.11.2 Merck Targeted Lung Cancer Drugs Product Offered
11.11.3 Merck Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck Main Business Overview
11.11.5 Merck Latest Developments
11.12 Bayer
11.12.1 Bayer Company Information
11.12.2 Bayer Targeted Lung Cancer Drugs Product Offered
11.12.3 Bayer Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Bayer Main Business Overview
11.12.5 Bayer Latest Developments
11.13 Daiichi Sankyo Company
11.13.1 Daiichi Sankyo Company Company Information
11.13.2 Daiichi Sankyo Company Targeted Lung Cancer Drugs Product Offered
11.13.3 Daiichi Sankyo Company Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Daiichi Sankyo Company Main Business Overview
11.13.5 Daiichi Sankyo Company Latest Developments
11.14 Shanghai Allist Pharmaceuticals
11.14.1 Shanghai Allist Pharmaceuticals Company Information
11.14.2 Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
11.14.3 Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Shanghai Allist Pharmaceuticals Main Business Overview
11.14.5 Shanghai Allist Pharmaceuticals Latest Developments
11.15 Betta Pharmaceuticals
11.15.1 Betta Pharmaceuticals Company Information
11.15.2 Betta Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
11.15.3 Betta Pharmaceuticals Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Betta Pharmaceuticals Main Business Overview
11.15.5 Betta Pharmaceuticals Latest Developments
11.16 Jiangsu Hansoh Pharmaceutical
11.16.1 Jiangsu Hansoh Pharmaceutical Company Information
11.16.2 Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.16.3 Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
11.16.5 Jiangsu Hansoh Pharmaceutical Latest Developments
11.17 Dizal (Jiangsu) Pharmaceutical
11.17.1 Dizal (Jiangsu) Pharmaceutical Company Information
11.17.2 Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.17.3 Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Dizal (Jiangsu) Pharmaceutical Main Business Overview
11.17.5 Dizal (Jiangsu) Pharmaceutical Latest Developments
11.18 HUTCHMED (China) Limited
11.18.1 HUTCHMED (China) Limited Company Information
11.18.2 HUTCHMED (China) Limited Targeted Lung Cancer Drugs Product Offered
11.18.3 HUTCHMED (China) Limited Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 HUTCHMED (China) Limited Main Business Overview
11.18.5 HUTCHMED (China) Limited Latest Developments
11.19 Innovent Biologics
11.19.1 Innovent Biologics Company Information
11.19.2 Innovent Biologics Targeted Lung Cancer Drugs Product Offered
11.19.3 Innovent Biologics Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Innovent Biologics Main Business Overview
11.19.5 Innovent Biologics Latest Developments
11.20 Chia Tai Tianqing Pharmaceutical
11.20.1 Chia Tai Tianqing Pharmaceutical Company Information
11.20.2 Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.20.3 Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
11.20.5 Chia Tai Tianqing Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Lung Cancer Drugs Market Size (2021-2032)
2.1.2 Targeted Lung Cancer Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Targeted Lung Cancer Drugs by Country/Region (2021, 2025 & 2032)
2.2 Targeted Lung Cancer Drugs Segment by Type
2.2.1 EGFR-Targeted Drugs
2.2.2 ALK-Targeted Drugs
2.2.3 ROS1-Targeted Drugs
2.2.4 KRAS G12C-Targeted Drugs
2.2.5 MET-Targeted Drugs
2.2.6 RET-Targeted Drugs
2.2.7 Targeted Lung Cancer Drugs Market Size by Type
2.2.7.1 Targeted Lung Cancer Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
2.3 Targeted Lung Cancer Drugs Segment by Drugs Type
2.3.1 Small-Molecule Tyrosine Kinase Inhibitors
2.3.2 Small-Molecule RAS Inhibitors
2.3.3 Monoclonal Antibodies
2.3.4 Bispecific Antibodies
2.3.5 Antibody-Drug Conjugates
2.3.6 Targeted Lung Cancer Drugs Market Size by Drugs Type
2.3.6.1 Targeted Lung Cancer Drugs Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032)
2.3.6.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type (2021-2026)
2.4 Targeted Lung Cancer Drugs Segment by Route of Administration
2.4.1 Oral Tablets
2.4.2 Oral Capsules
2.4.3 Oral Solutions
2.4.4 Intravenous Injections
2.4.5 Subcutaneous Injections
2.4.6 Targeted Lung Cancer Drugs Market Size by Route of Administration
2.4.6.1 Targeted Lung Cancer Drugs Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.6.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration (2021-2026)
2.5 Targeted Lung Cancer Drugs Segment by Application
2.5.1 Non-Small Cell Lung Cancer
2.5.2 Small Cell Lung Cancer
2.5.3 Lung Adenocarcinoma
2.5.4 Lung Squamous Cell Carcinoma
2.5.5 Early-Stage Resectable Lung Cancer
2.5.6 Other
2.5.7 Targeted Lung Cancer Drugs Market Size by Application
2.5.7.1 Targeted Lung Cancer Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
3 TARGETED LUNG CANCER DRUGS MARKET SIZE BY PLAYER
3.1 Targeted Lung Cancer Drugs Market Size Market Share by Player
3.1.1 Global Targeted Lung Cancer Drugs Revenue by Player (2021-2026)
3.1.2 Global Targeted Lung Cancer Drugs Revenue Market Share by Player (2021-2026)
3.2 Global Targeted Lung Cancer Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED LUNG CANCER DRUGS BY REGION
4.1 Targeted Lung Cancer Drugs Market Size by Region (2021-2026)
4.2 Global Targeted Lung Cancer Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.4 APAC Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.5 Europe Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
4.6 Middle East & Africa Targeted Lung Cancer Drugs Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Targeted Lung Cancer Drugs Market Size by Country (2021-2026)
5.2 Americas Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
5.3 Americas Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Lung Cancer Drugs Market Size by Region (2021-2026)
6.2 APAC Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
6.3 APAC Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Lung Cancer Drugs Market Size by Country (2021-2026)
7.2 Europe Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
7.3 Europe Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Lung Cancer Drugs by Region (2021-2026)
8.2 Middle East & Africa Targeted Lung Cancer Drugs Market Size by Type (2021-2026)
8.3 Middle East & Africa Targeted Lung Cancer Drugs Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED LUNG CANCER DRUGS MARKET FORECAST
10.1 Global Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.1.1 Global Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.1.2 Americas Targeted Lung Cancer Drugs Forecast
10.1.3 APAC Targeted Lung Cancer Drugs Forecast
10.1.4 Europe Targeted Lung Cancer Drugs Forecast
10.1.5 Middle East & Africa Targeted Lung Cancer Drugs Forecast
10.2 Americas Targeted Lung Cancer Drugs Forecast by Country (2027-2032)
10.2.1 United States Market Targeted Lung Cancer Drugs Forecast
10.2.2 Canada Market Targeted Lung Cancer Drugs Forecast
10.2.3 Mexico Market Targeted Lung Cancer Drugs Forecast
10.2.4 Brazil Market Targeted Lung Cancer Drugs Forecast
10.3 APAC Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.3.1 China Targeted Lung Cancer Drugs Market Forecast
10.3.2 Japan Market Targeted Lung Cancer Drugs Forecast
10.3.3 Korea Market Targeted Lung Cancer Drugs Forecast
10.3.4 Southeast Asia Market Targeted Lung Cancer Drugs Forecast
10.3.5 India Market Targeted Lung Cancer Drugs Forecast
10.3.6 Australia Market Targeted Lung Cancer Drugs Forecast
10.4 Europe Targeted Lung Cancer Drugs Forecast by Country (2027-2032)
10.4.1 Germany Market Targeted Lung Cancer Drugs Forecast
10.4.2 France Market Targeted Lung Cancer Drugs Forecast
10.4.3 UK Market Targeted Lung Cancer Drugs Forecast
10.4.4 Italy Market Targeted Lung Cancer Drugs Forecast
10.4.5 Russia Market Targeted Lung Cancer Drugs Forecast
10.5 Middle East & Africa Targeted Lung Cancer Drugs Forecast by Region (2027-2032)
10.5.1 Egypt Market Targeted Lung Cancer Drugs Forecast
10.5.2 South Africa Market Targeted Lung Cancer Drugs Forecast
10.5.3 Israel Market Targeted Lung Cancer Drugs Forecast
10.5.4 Turkey Market Targeted Lung Cancer Drugs Forecast
10.6 Global Targeted Lung Cancer Drugs Forecast by Type (2027-2032)
10.7 Global Targeted Lung Cancer Drugs Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Targeted Lung Cancer Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Targeted Lung Cancer Drugs Product Offered
11.1.3 AstraZeneca Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Targeted Lung Cancer Drugs Product Offered
11.2.3 Roche Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Targeted Lung Cancer Drugs Product Offered
11.3.3 Pfizer Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Targeted Lung Cancer Drugs Product Offered
11.4.3 Novartis Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Targeted Lung Cancer Drugs Product Offered
11.5.3 Johnson & Johnson Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Amgen
11.6.1 Amgen Company Information
11.6.2 Amgen Targeted Lung Cancer Drugs Product Offered
11.6.3 Amgen Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Amgen Main Business Overview
11.6.5 Amgen Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Targeted Lung Cancer Drugs Product Offered
11.7.3 Bristol Myers Squibb Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Information
11.8.2 Eli Lilly and Company Targeted Lung Cancer Drugs Product Offered
11.8.3 Eli Lilly and Company Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Eli Lilly and Company Main Business Overview
11.8.5 Eli Lilly and Company Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Targeted Lung Cancer Drugs Product Offered
11.9.3 Takeda Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Targeted Lung Cancer Drugs Product Offered
11.10.3 Boehringer Ingelheim Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Boehringer Ingelheim Main Business Overview
11.10.5 Boehringer Ingelheim Latest Developments
11.11 Merck
11.11.1 Merck Company Information
11.11.2 Merck Targeted Lung Cancer Drugs Product Offered
11.11.3 Merck Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck Main Business Overview
11.11.5 Merck Latest Developments
11.12 Bayer
11.12.1 Bayer Company Information
11.12.2 Bayer Targeted Lung Cancer Drugs Product Offered
11.12.3 Bayer Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Bayer Main Business Overview
11.12.5 Bayer Latest Developments
11.13 Daiichi Sankyo Company
11.13.1 Daiichi Sankyo Company Company Information
11.13.2 Daiichi Sankyo Company Targeted Lung Cancer Drugs Product Offered
11.13.3 Daiichi Sankyo Company Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Daiichi Sankyo Company Main Business Overview
11.13.5 Daiichi Sankyo Company Latest Developments
11.14 Shanghai Allist Pharmaceuticals
11.14.1 Shanghai Allist Pharmaceuticals Company Information
11.14.2 Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
11.14.3 Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Shanghai Allist Pharmaceuticals Main Business Overview
11.14.5 Shanghai Allist Pharmaceuticals Latest Developments
11.15 Betta Pharmaceuticals
11.15.1 Betta Pharmaceuticals Company Information
11.15.2 Betta Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
11.15.3 Betta Pharmaceuticals Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Betta Pharmaceuticals Main Business Overview
11.15.5 Betta Pharmaceuticals Latest Developments
11.16 Jiangsu Hansoh Pharmaceutical
11.16.1 Jiangsu Hansoh Pharmaceutical Company Information
11.16.2 Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.16.3 Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
11.16.5 Jiangsu Hansoh Pharmaceutical Latest Developments
11.17 Dizal (Jiangsu) Pharmaceutical
11.17.1 Dizal (Jiangsu) Pharmaceutical Company Information
11.17.2 Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.17.3 Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Dizal (Jiangsu) Pharmaceutical Main Business Overview
11.17.5 Dizal (Jiangsu) Pharmaceutical Latest Developments
11.18 HUTCHMED (China) Limited
11.18.1 HUTCHMED (China) Limited Company Information
11.18.2 HUTCHMED (China) Limited Targeted Lung Cancer Drugs Product Offered
11.18.3 HUTCHMED (China) Limited Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 HUTCHMED (China) Limited Main Business Overview
11.18.5 HUTCHMED (China) Limited Latest Developments
11.19 Innovent Biologics
11.19.1 Innovent Biologics Company Information
11.19.2 Innovent Biologics Targeted Lung Cancer Drugs Product Offered
11.19.3 Innovent Biologics Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Innovent Biologics Main Business Overview
11.19.5 Innovent Biologics Latest Developments
11.20 Chia Tai Tianqing Pharmaceutical
11.20.1 Chia Tai Tianqing Pharmaceutical Company Information
11.20.2 Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Product Offered
11.20.3 Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
11.20.5 Chia Tai Tianqing Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Lung Cancer Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Lung Cancer Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of EGFR-Targeted Drugs
Table 4. Major Players of ALK-Targeted Drugs
Table 5. Major Players of ROS1-Targeted Drugs
Table 6. Major Players of KRAS G12C-Targeted Drugs
Table 7. Major Players of MET-Targeted Drugs
Table 8. Major Players of RET-Targeted Drugs
Table 9. Targeted Lung Cancer Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Small-Molecule Tyrosine Kinase Inhibitors
Table 13. Major Players of Small-Molecule RAS Inhibitors
Table 14. Major Players of Monoclonal Antibodies
Table 15. Major Players of Bispecific Antibodies
Table 16. Major Players of Antibody-Drug Conjugates
Table 17. Targeted Lung Cancer Drugs Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted Lung Cancer Drugs Market Size by Drugs Type (2021-2026) & ($ millions)
Table 19. Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type (2021-2026)
Table 20. Major Players of Oral Tablets
Table 21. Major Players of Oral Capsules
Table 22. Major Players of Oral Solutions
Table 23. Major Players of Intravenous Injections
Table 24. Major Players of Subcutaneous Injections
Table 25. Targeted Lung Cancer Drugs Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Targeted Lung Cancer Drugs Market Size by Route of Administration (2021-2026) & ($ millions)
Table 27. Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration (2021-2026)
Table 28. Targeted Lung Cancer Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 29. Global Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 30. Global Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Table 31. Global Targeted Lung Cancer Drugs Revenue by Player (2021-2026) & ($ millions)
Table 32. Global Targeted Lung Cancer Drugs Revenue Market Share by Player (2021-2026)
Table 33. Targeted Lung Cancer Drugs Key Players Head office and Products Offered
Table 34. Targeted Lung Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 35. New Products and Potential Entrants
Table 36. Mergers & Acquisitions, Expansion
Table 37. Global Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 38. Global Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Table 39. Global Targeted Lung Cancer Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 40. Global Targeted Lung Cancer Drugs Revenue Market Share by Country/Region (2021-2026)
Table 41. Americas Targeted Lung Cancer Drugs Market Size by Country (2021-2026) & ($ millions)
Table 42. Americas Targeted Lung Cancer Drugs Market Size Market Share by Country (2021-2026)
Table 43. Americas Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 44. Americas Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Table 45. Americas Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 46. Americas Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Table 47. APAC Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 48. APAC Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Table 49. APAC Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 50. APAC Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 51. Europe Targeted Lung Cancer Drugs Market Size by Country (2021-2026) & ($ millions)
Table 52. Europe Targeted Lung Cancer Drugs Market Size Market Share by Country (2021-2026)
Table 53. Europe Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 54. Europe Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 55. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 56. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 57. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 58. Key Market Drivers & Growth Opportunities of Targeted Lung Cancer Drugs
Table 59. Key Market Challenges & Risks of Targeted Lung Cancer Drugs
Table 60. Key Industry Trends of Targeted Lung Cancer Drugs
Table 61. Global Targeted Lung Cancer Drugs Market Size Forecast by Region (2027-2032) & ($ millions)
Table 62. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Region (2027-2032)
Table 63. Global Targeted Lung Cancer Drugs Market Size Forecast by Type (2027-2032) & ($ millions)
Table 64. Global Targeted Lung Cancer Drugs Market Size Forecast by Application (2027-2032) & ($ millions)
Table 65. AstraZeneca Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 66. AstraZeneca Targeted Lung Cancer Drugs Product Offered
Table 67. AstraZeneca Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. AstraZeneca Main Business
Table 69. AstraZeneca Latest Developments
Table 70. Roche Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 71. Roche Targeted Lung Cancer Drugs Product Offered
Table 72. Roche Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Roche Main Business
Table 74. Roche Latest Developments
Table 75. Pfizer Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 76. Pfizer Targeted Lung Cancer Drugs Product Offered
Table 77. Pfizer Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Pfizer Main Business
Table 79. Pfizer Latest Developments
Table 80. Novartis Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 81. Novartis Targeted Lung Cancer Drugs Product Offered
Table 82. Novartis Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. Johnson & Johnson Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 86. Johnson & Johnson Targeted Lung Cancer Drugs Product Offered
Table 87. Johnson & Johnson Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Johnson & Johnson Main Business
Table 89. Johnson & Johnson Latest Developments
Table 90. Amgen Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 91. Amgen Targeted Lung Cancer Drugs Product Offered
Table 92. Amgen Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Amgen Main Business
Table 94. Amgen Latest Developments
Table 95. Bristol Myers Squibb Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 96. Bristol Myers Squibb Targeted Lung Cancer Drugs Product Offered
Table 97. Bristol Myers Squibb Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Bristol Myers Squibb Main Business
Table 99. Bristol Myers Squibb Latest Developments
Table 100. Eli Lilly and Company Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 101. Eli Lilly and Company Targeted Lung Cancer Drugs Product Offered
Table 102. Eli Lilly and Company Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Eli Lilly and Company Main Business
Table 104. Eli Lilly and Company Latest Developments
Table 105. Takeda Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 106. Takeda Targeted Lung Cancer Drugs Product Offered
Table 107. Takeda Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Takeda Main Business
Table 109. Takeda Latest Developments
Table 110. Boehringer Ingelheim Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 111. Boehringer Ingelheim Targeted Lung Cancer Drugs Product Offered
Table 112. Boehringer Ingelheim Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Boehringer Ingelheim Main Business
Table 114. Boehringer Ingelheim Latest Developments
Table 115. Merck Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 116. Merck Targeted Lung Cancer Drugs Product Offered
Table 117. Merck Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Merck Main Business
Table 119. Merck Latest Developments
Table 120. Bayer Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 121. Bayer Targeted Lung Cancer Drugs Product Offered
Table 122. Bayer Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Bayer Main Business
Table 124. Bayer Latest Developments
Table 125. Daiichi Sankyo Company Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 126. Daiichi Sankyo Company Targeted Lung Cancer Drugs Product Offered
Table 127. Daiichi Sankyo Company Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Daiichi Sankyo Company Main Business
Table 129. Daiichi Sankyo Company Latest Developments
Table 130. Shanghai Allist Pharmaceuticals Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 131. Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
Table 132. Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Shanghai Allist Pharmaceuticals Main Business
Table 134. Shanghai Allist Pharmaceuticals Latest Developments
Table 135. Betta Pharmaceuticals Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 136. Betta Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
Table 137. Betta Pharmaceuticals Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Betta Pharmaceuticals Main Business
Table 139. Betta Pharmaceuticals Latest Developments
Table 140. Jiangsu Hansoh Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 141. Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 142. Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Jiangsu Hansoh Pharmaceutical Main Business
Table 144. Jiangsu Hansoh Pharmaceutical Latest Developments
Table 145. Dizal (Jiangsu) Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 146. Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 147. Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Dizal (Jiangsu) Pharmaceutical Main Business
Table 149. Dizal (Jiangsu) Pharmaceutical Latest Developments
Table 150. HUTCHMED (China) Limited Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 151. HUTCHMED (China) Limited Targeted Lung Cancer Drugs Product Offered
Table 152. HUTCHMED (China) Limited Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. HUTCHMED (China) Limited Main Business
Table 154. HUTCHMED (China) Limited Latest Developments
Table 155. Innovent Biologics Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 156. Innovent Biologics Targeted Lung Cancer Drugs Product Offered
Table 157. Innovent Biologics Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 158. Innovent Biologics Main Business
Table 159. Innovent Biologics Latest Developments
Table 160. Chia Tai Tianqing Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 161. Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 162. Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 163. Chia Tai Tianqing Pharmaceutical Main Business
Table 164. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 1. Targeted Lung Cancer Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Targeted Lung Cancer Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of EGFR-Targeted Drugs
Table 4. Major Players of ALK-Targeted Drugs
Table 5. Major Players of ROS1-Targeted Drugs
Table 6. Major Players of KRAS G12C-Targeted Drugs
Table 7. Major Players of MET-Targeted Drugs
Table 8. Major Players of RET-Targeted Drugs
Table 9. Targeted Lung Cancer Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Small-Molecule Tyrosine Kinase Inhibitors
Table 13. Major Players of Small-Molecule RAS Inhibitors
Table 14. Major Players of Monoclonal Antibodies
Table 15. Major Players of Bispecific Antibodies
Table 16. Major Players of Antibody-Drug Conjugates
Table 17. Targeted Lung Cancer Drugs Market Size CAGR by Drugs Type (2021 VS 2025 VS 2032) & ($ millions)
Table 18. Global Targeted Lung Cancer Drugs Market Size by Drugs Type (2021-2026) & ($ millions)
Table 19. Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type (2021-2026)
Table 20. Major Players of Oral Tablets
Table 21. Major Players of Oral Capsules
Table 22. Major Players of Oral Solutions
Table 23. Major Players of Intravenous Injections
Table 24. Major Players of Subcutaneous Injections
Table 25. Targeted Lung Cancer Drugs Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 26. Global Targeted Lung Cancer Drugs Market Size by Route of Administration (2021-2026) & ($ millions)
Table 27. Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration (2021-2026)
Table 28. Targeted Lung Cancer Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 29. Global Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 30. Global Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Table 31. Global Targeted Lung Cancer Drugs Revenue by Player (2021-2026) & ($ millions)
Table 32. Global Targeted Lung Cancer Drugs Revenue Market Share by Player (2021-2026)
Table 33. Targeted Lung Cancer Drugs Key Players Head office and Products Offered
Table 34. Targeted Lung Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 35. New Products and Potential Entrants
Table 36. Mergers & Acquisitions, Expansion
Table 37. Global Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 38. Global Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Table 39. Global Targeted Lung Cancer Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 40. Global Targeted Lung Cancer Drugs Revenue Market Share by Country/Region (2021-2026)
Table 41. Americas Targeted Lung Cancer Drugs Market Size by Country (2021-2026) & ($ millions)
Table 42. Americas Targeted Lung Cancer Drugs Market Size Market Share by Country (2021-2026)
Table 43. Americas Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 44. Americas Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Table 45. Americas Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 46. Americas Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Table 47. APAC Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 48. APAC Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Table 49. APAC Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 50. APAC Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 51. Europe Targeted Lung Cancer Drugs Market Size by Country (2021-2026) & ($ millions)
Table 52. Europe Targeted Lung Cancer Drugs Market Size Market Share by Country (2021-2026)
Table 53. Europe Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 54. Europe Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 55. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Region (2021-2026) & ($ millions)
Table 56. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Type (2021-2026) & ($ millions)
Table 57. Middle East & Africa Targeted Lung Cancer Drugs Market Size by Application (2021-2026) & ($ millions)
Table 58. Key Market Drivers & Growth Opportunities of Targeted Lung Cancer Drugs
Table 59. Key Market Challenges & Risks of Targeted Lung Cancer Drugs
Table 60. Key Industry Trends of Targeted Lung Cancer Drugs
Table 61. Global Targeted Lung Cancer Drugs Market Size Forecast by Region (2027-2032) & ($ millions)
Table 62. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Region (2027-2032)
Table 63. Global Targeted Lung Cancer Drugs Market Size Forecast by Type (2027-2032) & ($ millions)
Table 64. Global Targeted Lung Cancer Drugs Market Size Forecast by Application (2027-2032) & ($ millions)
Table 65. AstraZeneca Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 66. AstraZeneca Targeted Lung Cancer Drugs Product Offered
Table 67. AstraZeneca Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. AstraZeneca Main Business
Table 69. AstraZeneca Latest Developments
Table 70. Roche Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 71. Roche Targeted Lung Cancer Drugs Product Offered
Table 72. Roche Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Roche Main Business
Table 74. Roche Latest Developments
Table 75. Pfizer Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 76. Pfizer Targeted Lung Cancer Drugs Product Offered
Table 77. Pfizer Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Pfizer Main Business
Table 79. Pfizer Latest Developments
Table 80. Novartis Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 81. Novartis Targeted Lung Cancer Drugs Product Offered
Table 82. Novartis Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. Johnson & Johnson Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 86. Johnson & Johnson Targeted Lung Cancer Drugs Product Offered
Table 87. Johnson & Johnson Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Johnson & Johnson Main Business
Table 89. Johnson & Johnson Latest Developments
Table 90. Amgen Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 91. Amgen Targeted Lung Cancer Drugs Product Offered
Table 92. Amgen Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Amgen Main Business
Table 94. Amgen Latest Developments
Table 95. Bristol Myers Squibb Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 96. Bristol Myers Squibb Targeted Lung Cancer Drugs Product Offered
Table 97. Bristol Myers Squibb Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Bristol Myers Squibb Main Business
Table 99. Bristol Myers Squibb Latest Developments
Table 100. Eli Lilly and Company Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 101. Eli Lilly and Company Targeted Lung Cancer Drugs Product Offered
Table 102. Eli Lilly and Company Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Eli Lilly and Company Main Business
Table 104. Eli Lilly and Company Latest Developments
Table 105. Takeda Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 106. Takeda Targeted Lung Cancer Drugs Product Offered
Table 107. Takeda Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Takeda Main Business
Table 109. Takeda Latest Developments
Table 110. Boehringer Ingelheim Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 111. Boehringer Ingelheim Targeted Lung Cancer Drugs Product Offered
Table 112. Boehringer Ingelheim Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Boehringer Ingelheim Main Business
Table 114. Boehringer Ingelheim Latest Developments
Table 115. Merck Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 116. Merck Targeted Lung Cancer Drugs Product Offered
Table 117. Merck Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Merck Main Business
Table 119. Merck Latest Developments
Table 120. Bayer Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 121. Bayer Targeted Lung Cancer Drugs Product Offered
Table 122. Bayer Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Bayer Main Business
Table 124. Bayer Latest Developments
Table 125. Daiichi Sankyo Company Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 126. Daiichi Sankyo Company Targeted Lung Cancer Drugs Product Offered
Table 127. Daiichi Sankyo Company Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Daiichi Sankyo Company Main Business
Table 129. Daiichi Sankyo Company Latest Developments
Table 130. Shanghai Allist Pharmaceuticals Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 131. Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
Table 132. Shanghai Allist Pharmaceuticals Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Shanghai Allist Pharmaceuticals Main Business
Table 134. Shanghai Allist Pharmaceuticals Latest Developments
Table 135. Betta Pharmaceuticals Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 136. Betta Pharmaceuticals Targeted Lung Cancer Drugs Product Offered
Table 137. Betta Pharmaceuticals Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Betta Pharmaceuticals Main Business
Table 139. Betta Pharmaceuticals Latest Developments
Table 140. Jiangsu Hansoh Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 141. Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 142. Jiangsu Hansoh Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Jiangsu Hansoh Pharmaceutical Main Business
Table 144. Jiangsu Hansoh Pharmaceutical Latest Developments
Table 145. Dizal (Jiangsu) Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 146. Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 147. Dizal (Jiangsu) Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Dizal (Jiangsu) Pharmaceutical Main Business
Table 149. Dizal (Jiangsu) Pharmaceutical Latest Developments
Table 150. HUTCHMED (China) Limited Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 151. HUTCHMED (China) Limited Targeted Lung Cancer Drugs Product Offered
Table 152. HUTCHMED (China) Limited Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. HUTCHMED (China) Limited Main Business
Table 154. HUTCHMED (China) Limited Latest Developments
Table 155. Innovent Biologics Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 156. Innovent Biologics Targeted Lung Cancer Drugs Product Offered
Table 157. Innovent Biologics Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 158. Innovent Biologics Main Business
Table 159. Innovent Biologics Latest Developments
Table 160. Chia Tai Tianqing Pharmaceutical Details, Company Type, Targeted Lung Cancer Drugs Area Served and Its Competitors
Table 161. Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Product Offered
Table 162. Chia Tai Tianqing Pharmaceutical Targeted Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 163. Chia Tai Tianqing Pharmaceutical Main Business
Table 164. Chia Tai Tianqing Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Targeted Lung Cancer Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Lung Cancer Drugs Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Lung Cancer Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Lung Cancer Drugs Sales Market Share by Country/Region (2025)
Figure 8. Targeted Lung Cancer Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Lung Cancer Drugs Market Size Market Share by Type in 2025
Figure 10. Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type in 2025
Figure 11. Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration in 2025
Figure 12. Targeted Lung Cancer Drugs in Non-Small Cell Lung Cancer
Figure 13. Global Targeted Lung Cancer Drugs Market: Non-Small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 14. Targeted Lung Cancer Drugs in Small Cell Lung Cancer
Figure 15. Global Targeted Lung Cancer Drugs Market: Small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 16. Targeted Lung Cancer Drugs in Lung Adenocarcinoma
Figure 17. Global Targeted Lung Cancer Drugs Market: Lung Adenocarcinoma (2021-2026) & ($ millions)
Figure 18. Targeted Lung Cancer Drugs in Lung Squamous Cell Carcinoma
Figure 19. Global Targeted Lung Cancer Drugs Market: Lung Squamous Cell Carcinoma (2021-2026) & ($ millions)
Figure 20. Targeted Lung Cancer Drugs in Early-Stage Resectable Lung Cancer
Figure 21. Global Targeted Lung Cancer Drugs Market: Early-Stage Resectable Lung Cancer (2021-2026) & ($ millions)
Figure 22. Targeted Lung Cancer Drugs in Other
Figure 23. Global Targeted Lung Cancer Drugs Market: Other (2021-2026) & ($ millions)
Figure 24. Global Targeted Lung Cancer Drugs Market Size Market Share by Application in 2025
Figure 25. Global Targeted Lung Cancer Drugs Revenue Market Share by Player in 2025
Figure 26. Global Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Figure 27. Americas Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 28. APAC Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 29. Europe Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 31. Americas Targeted Lung Cancer Drugs Value Market Share by Country in 2025
Figure 32. United States Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Targeted Lung Cancer Drugs Market Size Market Share by Region in 2025
Figure 37. APAC Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 38. APAC Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 39. China Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 43. India Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Targeted Lung Cancer Drugs Market Size Market Share by Country in 2025
Figure 46. Europe Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 47. Europe Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 48. Germany Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 49. France Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 62. APAC Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 63. Europe Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 65. United States Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 66. Canada Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 67. Mexico Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 68. Brazil Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 69. China Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 70. Japan Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 71. Korea Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 73. India Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 74. Australia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 75. Germany Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 76. France Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 77. UK Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 78. Italy Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 79. Russia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 80. Egypt Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 81. South Africa Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 82. Israel Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 83. Turkey Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 84. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 1. Targeted Lung Cancer Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Lung Cancer Drugs Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Targeted Lung Cancer Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Targeted Lung Cancer Drugs Sales Market Share by Country/Region (2025)
Figure 8. Targeted Lung Cancer Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Targeted Lung Cancer Drugs Market Size Market Share by Type in 2025
Figure 10. Global Targeted Lung Cancer Drugs Market Size Market Share by Drugs Type in 2025
Figure 11. Global Targeted Lung Cancer Drugs Market Size Market Share by Route of Administration in 2025
Figure 12. Targeted Lung Cancer Drugs in Non-Small Cell Lung Cancer
Figure 13. Global Targeted Lung Cancer Drugs Market: Non-Small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 14. Targeted Lung Cancer Drugs in Small Cell Lung Cancer
Figure 15. Global Targeted Lung Cancer Drugs Market: Small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 16. Targeted Lung Cancer Drugs in Lung Adenocarcinoma
Figure 17. Global Targeted Lung Cancer Drugs Market: Lung Adenocarcinoma (2021-2026) & ($ millions)
Figure 18. Targeted Lung Cancer Drugs in Lung Squamous Cell Carcinoma
Figure 19. Global Targeted Lung Cancer Drugs Market: Lung Squamous Cell Carcinoma (2021-2026) & ($ millions)
Figure 20. Targeted Lung Cancer Drugs in Early-Stage Resectable Lung Cancer
Figure 21. Global Targeted Lung Cancer Drugs Market: Early-Stage Resectable Lung Cancer (2021-2026) & ($ millions)
Figure 22. Targeted Lung Cancer Drugs in Other
Figure 23. Global Targeted Lung Cancer Drugs Market: Other (2021-2026) & ($ millions)
Figure 24. Global Targeted Lung Cancer Drugs Market Size Market Share by Application in 2025
Figure 25. Global Targeted Lung Cancer Drugs Revenue Market Share by Player in 2025
Figure 26. Global Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Figure 27. Americas Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 28. APAC Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 29. Europe Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Targeted Lung Cancer Drugs Market Size 2021-2026 ($ millions)
Figure 31. Americas Targeted Lung Cancer Drugs Value Market Share by Country in 2025
Figure 32. United States Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Targeted Lung Cancer Drugs Market Size Market Share by Region in 2025
Figure 37. APAC Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 38. APAC Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 39. China Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 43. India Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Targeted Lung Cancer Drugs Market Size Market Share by Country in 2025
Figure 46. Europe Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 47. Europe Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 48. Germany Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 49. France Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Targeted Lung Cancer Drugs Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Targeted Lung Cancer Drugs Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 62. APAC Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 63. Europe Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 65. United States Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 66. Canada Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 67. Mexico Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 68. Brazil Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 69. China Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 70. Japan Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 71. Korea Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 73. India Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 74. Australia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 75. Germany Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 76. France Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 77. UK Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 78. Italy Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 79. Russia Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 80. Egypt Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 81. South Africa Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 82. Israel Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 83. Turkey Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
Figure 84. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Targeted Lung Cancer Drugs Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Targeted Lung Cancer Drugs Market Size 2027-2032 ($ millions)
